Position in NVS
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$0
New position
Shares Held
0
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2026
1 quarter on record
Derivatives in NVS
reported options exposure · as of Jun 30, 2026CallValue
$19,903
CallShares
127
PutValue
$40,120
PutShares
256
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Persistent Asset Partners Ltd holds $4,144,035 across 7 Drug Manufacturers - General names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
5,605 | $1,423,501 | |
| 2 | NVO |
Novo Nordisk A S
|
25,600 | $1,227,264 | |
| 3 | AZN |
Astrazeneca PLC
|
4,058 | $769,477 | |
| 4 | SNY |
Sanofi
|
14,750 | $629,235 | |
| 5 | LLY |
ELI LILLY & Co
|
56 | $67,168 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
194 | $24,509 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
50 | $2,881 |
All Filings in NVS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $40,120 | 256 | Put | Sole | 2026-08-07 | |
| 2026-06-30 | $19,903 | 127 | Call | Sole | 2026-08-07 | |
| No filing history on record for this holder in this stock. | ||||||